SequelSEC

BURZYNSKI RESEARCH INSTITUTE INC BZYR

In Vitro & In Vivo Diagnostic Substances · CIK 0000724445 · Fiscal year ends 0228

Revenue
$0
Fiscal year ended 2025-11-30
Operating income
-$1.29M
Fiscal year ended 2025-11-30
Free cash flow
Unavailable
Fiscal year ended 2025-11-30

BURZYNSKI RESEARCH INSTITUTE INC (BZYR) reported revenue of $0 and net income of -$1.29M for the fiscal year ended 2025-11-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from BURZYNSKI RESEARCH INSTITUTE INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under In Vitro & In Vivo Diagnostic Substances.

Income

BURZYNSKI RESEARCH INSTITUTE INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-11-30
Revenue$0
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$1.29M
Net income-$1.29M
Research & development$1.03M
Weighted-average diluted sharesUnavailable
Pretax income-$1.29M
Income tax expense$0
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$259.30K
Selling & marketingUnavailable

Balance

BURZYNSKI RESEARCH INSTITUTE INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-11-30
Cash & equivalents$2.16K
Total assets$2.26K
Current assets$2.26K
Total liabilities$69.61K
Current liabilitiesUnavailable
Total equity incl. NCI-$67.34K
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$45.10K

Cash flow

BURZYNSKI RESEARCH INSTITUTE INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-11-30
Operating cash flow-$257.78K
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flow$259.34K
Net change in cashUnavailable
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

BURZYNSKI RESEARCH INSTITUTE INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-11-30
Free cash flowUnavailable
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratioUnavailable
Revenue YoY growthUnavailable
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BZYR in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-01-13View SEC filing
10-Q · Filed 2025-10-14View SEC filing
10-Q · Filed 2025-07-15View SEC filing
10-K · Filed 2025-05-20View SEC filing
10-Q · Filed 2025-01-13View SEC filing
10-Q · Filed 2024-10-10View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.